Article
Oncology
Axel S. Merseburger, Gerhardt Attard, Lennart astroem, Vsevolod B. Matveev, Sergio Bracarda, Adil Esen, Susan Feyerabend, Elzbieta Senkus, Marta Lopez-Brea Piqueras, Gunther Boysen, Georgia Gourgioti, Karla Martins, Simon Chowdhury
Summary: The study found that continuing enzalutamide with docetaxel and androgen deprivation therapy can delay progression in men with mCRPC, supporting the idea that enzalutamide maintenance may control persistent androgen-dependent clones.
Article
Oncology
Vincenza Conteduca, Daniel Wetterskog, Elena Castro, Emanuela Scarpi, Nuria Romero-Laorden, Giorgia Gurioli, Anuradha Jayaram, Cristian Lolli, Giuseppe Schepisi, Anna Wingate, Chiara Casadei, Rebeca Lozano, Nicole Brighi, Isabel M. Aragon, Mercedes Marin-Aguilera, Enrique Gonzalez-Billalabeitia, Begona Mellado, David Olmos, Gerhardt Attard, Ugo De Giorgi
Summary: The relevance of plasma AR in the overall management of CRPC patients receiving different docetaxel doses is currently unknown.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Urology & Nephrology
Ravi A. Madan, Fatima H. Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen, Inger Rosner, Marc R. Theoret, Lisa Cordes, Marijo Bilusic, Cody J. Peer, Nancy A. Dawson, Anna Couvillon, Amy Hankin, Moniquea Williams, Guin Chun, Helen Owens, Jennifer L. Marte, Min-Jung Lee, Yusuke Tomita, Akira Yuno, Jane B. Trepel, Sunmin Lee, Seth M. Steinberg, James L. Gulley, William D. Figg, William L. Dahut
Summary: The study evaluated the safety and efficacy of cabozantinib combined with docetaxel in mCRPC patients. Cabozantinib was found to be safely added to docetaxel treatment with potential enhanced efficacy. However, due to limited patient accrual, the phase 2 study was terminated early.
Article
Chemistry, Medicinal
Yujie Huang, You Zhai, Meijia Wu, Chengdong Chang, Jindan Luo, Dongsheng Hong, Qingwei Zhao, Yao Dai, Jian Liu
Summary: This study investigated the role of mTORC2 signaling in docetaxel-resistant prostate cells to find potential methods for clinical treatment. The expression of mTORC2 is crucial for docetaxel drug resistance in prostate cells. The mTORC1/2 inhibitor AZD8055 disrupts mTORC2 kinase activity more significantly than the mTORC1 inhibitor Rapamycin, leading to decreased docetaxel-mediated resistance. Therefore, reversing docetaxel resistance may become a therapeutic option for the treatment of metastatic castration-resistant prostate cancer patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Biology
Kevin J. Tu, Sanjit K. Roy, Zachery Keepers, Manas R. Gartia, Hem D. Shukla, Nrusingh C. Biswal
Summary: The study investigates the effectiveness and molecular characteristics of the combination therapy of Docetaxel (DXL) and radiation in vitro. The results suggest that DXL sensitizes castration-resistant prostate cancer (CRPC) cells to radiation by downregulating CAV-1.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2023)
Article
Medicine, General & Internal
Xiaojuan Zhu, Zhenguo Shi, Shegan Gao, Xiaohong Wang, Pei Wang, Chongzhao Kang, Fangzong Zhao, Peng Hou
Summary: This case report presented a patient with high-risk advanced prostate cancer and old pulmonary tuberculosis who achieved complete remission after a combination of treatments. The importance of endocrine therapy, radiotherapy for reducing tumor burden, and early application of abiraterone in high-risk mCRPC were highlighted. Long-term use of prednisone can be appropriately reduced in mCRPC with old PTB for a satisfactory curative effect, but more prospective trials are needed for a definite recommendation.
Article
Oncology
Wei Ning, Pengkang Chang, Ji Zheng, Fan He
Summary: This case report highlights the potential effectiveness and safety of a second docetaxel rechallenge as a later-line treatment strategy for patients with mCRPC who are concerned about the high costs of multigene molecular testing and PARP inhibitors, as well as repeated prostate needle biopsy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Atefeh Deris, Mahdi Sohrabi-Haghighat
Summary: Patients with mCRPC are classified into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. Drug-resistant cells may hinder successful outcomes in the latter two groups. To overcome this challenge, a combination of Docetaxel and Abiraterone is proposed to control both the overall cancer cell population and the drug-resistant subpopulation. Evolutionary Game Theory (EGT) is used as a mathematical modeling approach to study the competition and evolution of mCRPC cancer phenotypes.
Article
Urology & Nephrology
Evan Y. Yu, Michael P. Kolinsky, William R. Berry, Margitta Retz, Loic Mourey, Josep M. Piulats, Leonard J. Appleman, Emanuela Romano, Gwenaelle Gravis, Howard Gurney, Martin Bogemann, Urban Emmenegger, Anthony M. Joshua, Mark Linch, Srikala Sridhar, Henry J. Conter, Brigitte Laguerre, Christophe Massard, Xin Tong Li, Charles Schloss, Christian H. Poehlein, Johann S. de Bono
Summary: The study evaluated the efficacy and safety of pembrolizumab combined with docetaxel and prednisone in patients with mCRPC, showing promising antitumor activity and manageable safety in this patient population.
Article
Cell Biology
Senmao Li, Jindong Sheng, Zhenhua Liu, Yu Fan, Cuijian Zhang, Tianjing Lv, Shuai Hu, Jie Jin, Wei Yu, Yi Song
Summary: Recent studies have shown that the novel mTOR inhibitor AZD2014 has significant antitumor effects in prostate cancer, especially in inhibiting cell proliferation, apoptosis, and invasion. This provides a solid theoretical basis for the clinical application of AZD2014 in treating prostate cancer.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
(2021)
Article
Urology & Nephrology
Kristine Kreis, Dirk Horenkamp-Sonntag, Udo Schneider, Jan Zeidler, Gerd Glaeske, Lothar Weissbach
Summary: This study examined real-world haematological toxicity, overall survival, and treatment characteristics of docetaxel and cabazitaxel chemotherapy in mCRPC patients. The findings suggest that cabazitaxel treatment poses higher risk of haematological toxicities and shorter survival time, emphasizing the importance of strict indications when using cabazitaxel in mCRPC patients.
Article
Oncology
David Pook, Daniel M. Geynisman, Joan Carles, Filippo de Braud, Anthony M. Joshua, Jose Luis Perez-Gracia, Casilda Llacer Perez, Sang Joon Shin, Bruno Fang, Minal Barve, Marco Maruzzo, Sergio Bracarda, Miso Kim, Yannick Kerloeguen, Jorge Daniel Gallo, Sophia L. Maund, Adam Harris, Kuan-Chieh Huang, Victor Poon, Dhruvitkumar S. Sutaria, Howard Gurney
Summary: The combination of ipatasertib and rucaparib showed manageable safety in patients with metastatic castration-resistant prostate cancer, but did not demonstrate synergistic or additive antitumor activity in previously treated patients.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Baijun Dong, Liancheng Fan, Bin Yang, Wei Chen, Yonghong Li, Kaijie Wu, Fengbo Zhang, Haiying Dong, Huihua Cheng, Jiahua Pan, Yinjie Zhu, Chenfei Chi, Liang Dong, Jianjun Sha, Lei Li, Xudong Yao, Wei Xue
Summary: This study aimed to describe DNA repair gene aberrations in Chinese patients with mCRPC and evaluate the associations between key genomic alterations and clinical outcomes of different therapies. Alterations in CDK12 were significantly higher in the Chinese cohort compared with Western populations, and were associated with poorer PFS after abiraterone treatment. Patients with BRCA2 defects showed marked response to PARP inhibitors and platinum-based chemotherapy.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Oncology
Susan Halabi, Qian Yang, Akash Roy, Bin Luo, John C. Araujo, Christopher Logothetis, Cora N. Sternberg, Andrew J. Armstrong, Michael A. Carducci, Kim N. Chi, Johann S. de Bono, Daniel P. Petrylak, Karim Fizazi, Celestia S. Higano, Michael J. Morris, Dana E. Rathkopf, Fred Saad, Charles J. Ryan, Eric J. Small, William Kevin Kelly
Summary: This study validated a prognostic model of overall survival in men with metastatic, castration-resistant prostate cancer treated with docetaxel. The model accurately predicts the survival of patients and performs well across different racial, age, and treatment subgroups.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Zhenyu Yang, Yuchao Ni, Diwei Zhao, Yijun Zhang, Jun Wang, Lijuan Jiang, Dong Chen, Zhiming Wu, Yanjun Wang, Liru He, Yanxia Shi, Fangjian Zhou, Hao Zeng, Yonghong Li
Summary: The study showed that a corticosteroid switch from prednisone to dexamethasone is effective for mCRPC patients who progressed on A + P treatment. Patients with lower PSA levels at corticosteroid switch and/or longer mCRPC-free survival may benefit more from the corticosteroid switch.
